drugset / Trial / NCT01490060
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
RandomizedCrossoverOpen-labelTreatment
Summary
The goal of this clinical research study is to learn how different doses of fosaprepitant may effect how ifosfamide-based chemotherapy is absorbed by the body. Researchers also want to learn if fosaprepitant can help to control or prevent delayed nausea and/or vomiting that may be caused by chemotherapy. The safety of this drug will also be studied. Fosaprepitant is designed to block the natural substance in the brain that causes nausea and vomiting. This may help to prevent and/or control nausea and vomiting caused by chemotherapy.
Timeline
- Start
- 2012-05
- Primary completion
- 2016-03
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fosaprepitant | Other / unclassified | 150 mg | Intravenous |
| Subject | Ifosfamide | Small molecule | 2.5 g/kg | Intravenous |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 1500 mg/m2 | — |
| Background | Dexamethasone | Small molecule | 8 mg | Intravenous |
| Background | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Background | Vincristine | Small molecule | 2 mg | Intravenous |